NHS Patients Have No Access to Medical Cannabis 8 Years After Legalisation

In June 2018, Home Office officials held Billy Caldwell’s medicine in a vault while he lay in hospital. His mother, Charlotte Caldwell, fought. Ministers changed the law that November and let specialist doctors prescribe cannabis-based products for medicinal use. That was a real win. But ministers didn’t fund NHS prescribing. They didn’t require companies to run clinical trials. They left patients to private clinics and producers. So the legal change became a private prescription market.

Charlotte Caldwell puts the fight plainly: “In June 2018, I watched Billy become desperately ill after his lifesaving medicine was confiscated at Heathrow. While my son lay in hospital, the medicine we had fought to bring home was being held just miles away in the vaults of the Home Office.”

The law changed after that fight but ministers didn’t build an NHS route. NHS managers ration specialist referrals and ministers keep budgets tight. Working-class patients pay taxes for the NHS and then pay again for a private script, buy on the illicit market, or they go without. Wealthier patients can afford the private route but that’s not available to much of the working class. That’s the class divide in medicine at play.

Caldwell asks the question ministers and industry avoid: “When the law changed that November, I believed other patients would finally have a proper route to treatment. Eight years later, we must ask a difficult question: have we built a prescription market without building an adequate pathway to NHS care?”

Caldwell challenges cannabis businesses to fund rigorous trials on safety, effectiveness, dosing and cost-effectiveness. She says: “Another product on a private prescription list is not, by itself, another step towards NHS access.” And: “Selling products cannot be the end of the ambition.” But under capitalism, selling products is the ambition. A trial costs money and may show a product is weak. A private prescription list generates revenue now. Companies don’t fund trials voluntarily because the private market pays faster. Capitalists invest where they expect profit, not where patients need evidence.

Caldwell also wants a separate, evidence-led approach to adult-use cannabis. She says: “Patients need treatment based on clinical need. Adults seeking cannabis for non-medical reasons need a separate policy discussion, rather than a prescription being their only legal route.”

Through TRACD — Transparent, Regulated Adult-use Controlled Data — she’s developing a tightly controlled scientific adult-use pilot. TRACD is facilitating controlled, regulated recreational cannabis pilots across the UK, Jersey, Guernsey and the Isle of Man, generating long-term data to support evidence-based cannabis legislation.

TRACD launched a survey for eligible adults who have consumed or purchased cannabis in the past 12 months, including prescription patients and people obtaining cannabis through the illicit market. The survey gathers anonymised responses and aims to build a fuller picture of respondents’ experiences.

Billy’s family forced ministers to change the law. That victory mattered, but ministers conceded the right to prescribe while leaving private businesses to charge for access. Companies can now earn money from patients whose needs the government still refuses to meet through the NHS.

There’s no contradiction here for a state that exists to protect capitalist profits: ministers can recognise suffering, retreat under public pressure, and still leave working-class families facing a bill they can’t afford. Eight years after the medicine was locked in a Home Office vault, patients face another barrier. They can get through the clinic door only if they can pay.

Share post

The Team